AcelRx Pharmaceuticals Q3 EPS $(0.16) Beats $(0.22) Estimate, Sales $608K Miss $960K Estimate

AcelRx Pharmaceuticals (NASDAQ:ACRX) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.22) by 27.27 percent. This is a 23.81 percent increase over losses of $(0.21) per share

Benzinga · 11/06/2019 21:56

AcelRx Pharmaceuticals (NASDAQ:ACRX) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.22) by 27.27 percent. This is a 23.81 percent increase over losses of $(0.21) per share from the same period last year. The company reported quarterly sales of $608 thousand which missed the analyst consensus estimate of $960 thousand by 36.67 percent. This is a 61.27 percent increase over sales of $377 thousand the same period last year.